On July 19, 2022, the FDA approved Opzelura® (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years and older. It is the first FDA-approved medication to address repigmentation in vitiligo patients. Nonsegmental vitiligo is the most common form of vitiligo, and the condition involves a loss of pigment in patches of skin on the face, neck, scalp and around body openings such as mouth and genitals. It can also involve areas that tend to experience rubbing or impact, such as hands and arms. Vitiligo is a form of an autoimmune disorder when the immune system attacks the pigment cells in the skin. Opzelura® is a topical Janus kinase (JAK) inhibitor that blocks enzymes involved in activating immune cells. Opzelura® is also indicated for mild to moderate atopic dermatitis in select patients, ages 12 years and older. Two clinical trials were conducted to test the safety and effectiveness of Opzelura® in the treatment of nonsegmental vitiligo. In both trials, patients with the condition were randomized to treatment with Opzelura® or placebo cream twice daily for 24 weeks, followed by an additional 28 weeks of treatments during which all patients received Opzelura®. By the end of the initial 24-week treatment period, 30% of Opzelura® patients had at least 75% improvements in the facial Vitiligo Area Scoring Index, compared with 10% of placebo patients. Common adverse reactions to Opzelura® are application site acne, itching or redness, as well as common cold, headache, UTI, and fever. The use of Opzelura® in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.